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To evaluate potential roles of nitric oxide (NO) in the regulation of the endothelial lineage and
neovascular processes (vasculogenesis and angiogenesis) we evaluated endothelial nitric oxide
synthase (eNOS) and phosphorylated eNOS (p-eNOS) expression in 7.2–8.5 days post-coitum (dpc)
mouse embryos. Analysis revealed that p-eNOS(S1177) but not P-eNOS(S617) or P-eNOS(T495) was
expressed in a subpopulation of angioblasts (TAL-1þ/Flk-1þ/CD31/CD34/VE-Cadherin) at 7.2 dpc.
A role of the VEGF/Akt1/eNOS signaling pathway in the regulation of the endothelial cell (EC) lineage was
suggested by the strong correlation observed between cell division and p-eNOS(S1177) expression in both
angioblasts and embryonic endothelial cells (EECs, TAL-1þ/Flk-1þ/CD31þ/CD34þ/VE-Cadherinþ). Our
studies using Akt1 null mouse embryos show a reduction in p-eNOS(S1177) expression in angioblast and
EECs that is correlated with a decrease in endothelial cell proliferation and results in changes in VEGF-
induced vascular patterning. Further, we show that VEGF-mediated cell proliferation in Flk-1þ cells in
allantoic cultures is decreased by pharmacological inhibitors of the VEGF/Akt1/eNOS signaling pathways.
Taken together, our ﬁndings suggest that VEGF-mediated eNOS phosphorylation on Ser1177 regulates
angioblast and EEC division, which underlies the formation of blood vessels and vascular networks.
& 2012 Elsevier Inc. All rights reserved.Introduction
The production of NO in endothelial cells (ECs) is maintained
during homeostasis through endothelial nitric oxide synthase
(eNOS), which is regulated by mechanical stimuli, cytokines and
growth factors (Balligand et al., 2009; Dudzinski and Michel, 2007;
Kolluru et al., 2010). eNOS acts to regulate a number of biological
activities that are relevant to neovascular process, including gene
expression (Braam et al., 2004; Illi et al., 2008), stem cell/mesoderm
differentiation (Guthrie et al., 2005; Spallotta et al., 2010), cell growth
(Garcia-Cardena and Folkman, 1998; Hsieh et al., 2010; Iwakiri,
2011; Oliveira et al., 2008; Papapetropoulos et al., 1997) and matrix
remodeling (Chen and Wang, 2004). Despite the important roles
played by NO in adult ECs, its potential role(s) during embryonic
vascular development has not been extensively studied. Nath et al.
(2004) have shown that eNOS is expressed at 8.0 days post-coitum
(dpc) in ECs of the forming yolk sac vascular plexus, and that
inhibition of NO using NG-monomethyl-L-arginine (L-NMMA),
altered yolk sac vascularization.
The differentiation from mesoderm to angioblasts to embryo-
nic endothelial cells (EECs) is associated with the temporal
expression of the transcription factor SCL/TAL-1 (Drake et al., 1997;ll rights reserved.Kallianpur et al., 1994), the receptor tyrosine kinase VEGFR2 (also
known as Flk-1/KDR) (Shalaby et al., 1995) and cell–cell adhesion
molecules such as CD31/PECAM (Baldwin et al., 1994), CD34
(Wood et al., 1997; Young et al., 1995) and VE-Cadherin
(Lampugnani et al., 1992; Vittet et al., 1997). Using the expression
of key markers we have previously deﬁned angioblasts as TAL-
1þ/Flk-1þ/CD31/CD34/VE-Cadherin cells and EECs as TAL-
1þ/Flk-1þ/CD31þ/CD34þ/VE-Cadherinþ cells (Drake and
Fleming, 2000). Given the prominent role of vascular endothelial
growth factor (VEGF) in the regulation of neovascular processes
and the fact that VEGF has been shown to regulate NO production,
it is reasonable that NO acts downstream of the VEGF/Flk-1
signaling pathway in the EC lineage. VEGF signaling has been
shown to regulate NO levels by both increasing eNOS mRNA
expression levels (Papapetropoulos et al., 1997) and by post-
transcriptional modiﬁcations (Gelinas et al., 2002), in part
mediated by VEGF-dependent activation of the PI3 Kinase/Akt
pathway (Garcia-Cardena and Folkman, 1998; Lin and Sessa,
2006; Papapetropoulos et al., 1997). As part of a multimolecular
complex (the ‘‘signalosome’’) following VEGF stimulation, acti-
vated Akt1 acts to phosphorylate eNOS on Ser617 and Ser1177,
whereas phosphorylation of Thr495 by PKC has been shown to
have an inhibitory effect on NO production (Lin et al., 2003; Sessa,
2004). Moreover, eNOS can be phosphorylated on Ser1177 by
multiple kinases (i.e., Akt1, AMPK, PKA, PKG, and PKC) (Lin et al.,
2003; Schleicher et al., 2009; Sessa, 2004). The phosphorylated
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L-Arginine to L-Citrulline and NO (Eglen, 2006; Forstermann and
Sessa, 2011; Wyatt et al., 2004). This activity is enhanced by
HSP90 binding to p-eNOS(S1177), which inhibits the dephosphor-
ylation of p-eNOS(S1177) (Fontana et al., 2002). Additionally, HSP90
association with p-eNOS(S1177) has been shown to enhance the
S-nitrosylation of proteins by providing a more favorable steric
setting for the enzyme and the target protein (Fontana et al.,
2002).
A role for eNOS in the regulation of VEGF-mediated neovas-
cular processes is suggested by the study of Murohara et al.
(1998) which demonstrated that in animal models of hindlimb
ischemia eNOS modulates angiogenesis in response to tissue
ischemia. Mechanistically the study of Taylor et al. (2010) show-
ing that VEGF/Flk-1 signaling through Akt1, has a mitogenic effect
on ECs, and the study of Dai and Faber (2010) showing that mice
deﬁcient in eNOS exhibited decreased expression of 40 out of 44
cell cycle related genes following femoral artery ligation both
suggest that VEGF-mediated NO signaling acts to regulate angio-
genesis by controlling EC proliferation.
Given the prominent role of VEGF/Flk-1 signaling in the
development of the EC lineage and its role in the regulation of
eNOS we hypothesized that VEGF/Akt1-mediated NO signaling
may also act to control angioblast and EEC proliferation, which is
critical for the proper patterning of blood vessel. Our in vivo
studies using wild type and Akt1 null murine embryos show that
the expression of p-eNOS(S1177) is critical for cell proliferation in
angioblasts and EECs and is dependent on Akt1 signaling path-
way, whereas our in vitro studies using wild type, heterozygous
and homozygous Akt1 allantoic cultures show that the measured
changes in p-eNOS(S1177) expression and NO production following
VEGF treatment are responsible for the alteration in vascular
patterning via VEGF/Akt1 signaling pathway.Materials and methods
Drugs and reagents
Primary antibodies: rabbit polyclonal antimouse TAL-1/SCL was
obtained from Stephen J. Brandt (Vanderbilt University and
Veterans Affairs Medical Center, Nashville, TN, USA). Rat mono-
clonal antimouse CD31/PECAM, rat monoclonal antimouse
CD102/ICAM2, mouse monoclonal antihuman eNOS, rat mono-
clonal antimouse Flk-1 and rat monoclonal antimouse FITC-
conjugated Flk-1 were purchased from BD Pharmingen (San
Diego, CA, USA). Rabbit polyclonal antimouse p-eNOS(S1177), was
purchased from Cell Signaling Technology (Danvers, MA, USA).
Rabbit polyclonal antimouse phospho-histone H3-Ser10, rabbit
polyclonal antibovine p-eNOS(S617) and rabbit polyclonal antibo-
vine p-eNOS(T495) were purchased from Millipore (Billerica, MA,
USA). Rabbit polyclonal antimouse iNOS was purchased from
Abcam (Cambridge, MA, USA). Secondary antibodies: donkey
anti-rabbit, antimouse and anti-rat secondary ﬂuorochrome-
conjugated antibodies (Jackson Immunological Research Labs,
Inc., West Grove, PA, USA). Growth factors and inhibitors: Vascular
Endothelial Growth Factor-165 (VEGF-A, used at 50 ng/ml) and
recombinant mouse sFlt-1 (used at 3 g/ml) were purchased from
R&D Systems (Minneapolis, MN, USA). Drugs: L-NIO (N5-(1-
iminoethyl)-L-ornithine, dihydrochloride, used at 100 M) was
purchased from EMD Chemicals (Rockland, MA, USA). Resveratrol
(3,5,40-trihydroxy-trans-stilbene, used at 20 M) and LY294002
(2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, used at
20 M) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
SU1498 (used at 10 M) was purchased by Calbiochem (La Jolla,
CA, USA).Whole-mount immunolabeling
Isolation of mouse embryos was performed as previously
described (Drake and Fleming, 2000). Brieﬂy, CD1/ICR pregnant
mice (Harlan Laboratories, Indianapolis, IN, USA) and Akt1 knock-
out mice (kindly provided by Dr. Philip N. Tsichlis, Molecular
Oncology Research Institute, Tufts-New England Medical Center,
Boston, MA, USA (Mao et al., 2007) and backcrossed onto C57Bl6
background) were sacriﬁced by cervical dislocation and embryos at
7.0–8.5 days post-coitum (dpc) (0.5 dpc, plug date) were dissected
free of the uterine muscle and decidua and placed into embryonic
phosphate-buffered saline (EPBS, 4 1C). Reichert0s membrane and
the ectoplacental cone were removed and the embryos ﬂattened by
cutting the yolk sac either lateral (7.0 dpc) or perpendicular to the
embryonic axis (8.5 dpc) and removing the amniotic sac. Flattened
embryos were ﬁxed in 4% paraformaldehyde for 60 min and
permeabilized in phosphate buffered saline/0.01% sodium azide
(PBSA) containing 0.02% Triton-X-100 (60 min). Embryos were
then exposed to a blocking solution (3% bovine serum albumin
(BSA)/PBSA, 5% donkey serum and 0.1% Triton-X-100) and then to
appropriate primary (SCL/TAL-1 10 mg/ml, eNOS 5 mg/ml, Flk-1
15 mg/ml, CD31 15 mg/ml, p-eNOS 15 mg/ml, phospho-histone
H3-Ser10 20 mg/ml) and secondary (10 mg/ml) antibodies (over-
night at 4 1C). For eNOS and p-eNOS immunolabeling, embryos
were ﬁrst exposed to eNOS primary antibodies followed by
secondary antibodies (overnight, 4 1C), washed three times for
20 min and then exposed to p-eNOS primary and secondary
antibodies (overnight, 4 1C). Embryos were incubated with Hoechst
stain (Invitrogen, Carlsbad, CA, USA) for 1 h at room temperature.
Embryos were mounted ventral side up using Fluorogel (Electron
Microscopy Sciences, Hatﬁeld, PA, USA). All aspects of animal
research were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals (Department of Health and
Human Services, NIH Publication No. 86-23, 1985 edition or
succeeding revised editions) and with guidelines set by the
Institutional Animal Care and Use Committee at the Medical
University of South Carolina.Allantoic isolation, culture and immunolabeling
For experiments conducted as part of this study we utilized
two modiﬁed allantoic culture systems (Argraves et al., 2002). For
morphometric analyses, allantoides were excised from embryos
isolated as described above, washed in PBSA (4 1C) and then
transferred into ﬁbronectin pre-coated Nunc 4-chambered culture
slides (Fisher Scientiﬁc Co., Suwanee, GA, USA) containing 500 ml
complete Dulbecco0s modiﬁed Eagle0s medium (DMEM, Invitro-
gen Ltd., Carlsbad, CA, USA), supplemented with 10% fetal bovine
serum (FBS, Atlanta Geologics, Atlanta, GA, USA), 1% penicillin/
streptomycin (P/S) and 1% L-Glutamine. For measurements of
the numbers of Flk-1-positive cells expressing p-eNOS(S1177),
phospho-histone H3 or NO, allantoic cultures (N¼10 per sample)
were pooled together, dissociated into single cells by trypsinization
and then plated into ﬁbronectin pre-coated Nunc 4-chambered
culture slides containing 500 ml complete DMEM. Explants and
single cells cultures were cultured at 37 1C in a 5% CO2 incubator
overnight. The following day the media was replaced with serum
starvation (SS) media (DMEM containing 1% FBS). Combinations
of compounds (VEGF alone and VEGF plus eNOS inhibitors) were
prepared in SS media and then added to individual wells.
After 5 h, allantoic cultures were ﬁxed in 4% paraformaldehyde
(1 h), permeabilized in 0.02% Triton-X/PBSA (20 min) blocked in
3% BSA/PBSA (1 h), and exposed sequentially to the appropriate
primary (CD102/ICAM2 15 mg/ml, eNOS 5 mg/ml, P-eNOS 15 mg/ml,
phospho-histone H3-Ser10 20 mg/ml) and secondary (10 mg/ml)
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and mounted as described above.
Intracellular NO detection by ﬂuorescence imaging
NO was detected by using DAF-FM diacetate (Invitrogen Ltd.,
Carlsbad, CA,USA) using an approach similar to the one proposed
by Paul et al. (2011). For morphological analysis of allantoic
cultures, intact allantoides were plated after their isolation,
whereas for measurement of the numbers of Flk-1þ cells produ-
cing NO, allantoides were pulled together, tryspinized and then
plated. Allantoic cells (either intact allantoic tissues or following
trysinization to obtain single cell culture) were plated on Nunc 8-
chambered culture slides pre-coated with ﬁbronectin containing
200 ml complete DMEM and allowed to adhere for 18 h in an
incubator at 37 1C in a 5% CO2 incubator. Cells were then rinsed
twice with DPBS, and 1 mM DAF-FM diacetate solution was
prepared freshly in Phenol Red Free DMEM (Invitrogen Ltd.,
Carlsbad, CA, USA) containing 0.5% FBS together with antibiotics
and L-glutamine. After 30 min, DAF-FM diacetate solution was
removed, cells were rinsed twice with DPBS and fresh PRF-SSM
was added for 30 min. Chemical inhibitors (i.e., L-NIO, resveratrol,
SU1498 and LY294002) were added to the PRF-SSM prior to VEGF
stimulation. Only rmsFlt-1 was added together with VEGF. VEGF
was added to the cells for 1 h in presence or absence of the
inhibitors. Cells were then ﬁxed in 2% PFA for 1 h and then
immunostained using antibodies to Flk-1 and p-eNOS(S1177). For
measurements of NO producing cells, 15 ﬁelds were imaged per
sample using a Leica DMI 4000 B ﬂuorescence microscope (Leica
Microsystems, Inc., Buffalo Grove, IL, USA) and NO-producing
Flk-1þ cells were counted.
Microscopy and image processing
Conventional ﬂuorescence images of some allantoic cultures were
obtained using a Leica DMR research grade microscope equipped
with Leica objectives (5, 10, 20/0.7 and 40/0.85) and a
SPOT-RT camera (Vashaw Scientiﬁc, Raleigh, NC, USA). Images were
acquired using the SPOT-RT 4.6.1.40 software. Embryos and some
allantoic cultures were analyzed using a Leica TCS SP5 AOBS Laser
Scanning Confocal Microscope (Leica Microsystems GmbH, Wetzlar,
Germany). Optical sectioning along the Z-axis was performed and the
images collapsed into a single focal plane using the manufacturer0s
software. Images were processed using NIH Image 1.37v software
(National Institutes of Health, Bethesda, MD, USA) and Adobe Photo-
shop CS5 (Adobe Systems, Inc., San Jose, CA, USA). For 3D reconstruc-
tions, images generated by using Leica TCS SP5 LSCMwere processed
by AMIRA 5.3.3 (Visage Imaging, Inc., San Diego, CA, USA).
Mitotic index calculations in single cell cultures
To determine mitotic index (MI) of Flk-1þ cells using ﬂuores-
cence imaging in single cell allantoic cultures, pooled allantoic
cultures were treated and subjected to immunostaining with
antibodies to Flk-1 and phospho-histone H3 as described above.
Ten ﬁelds for sample (N¼3) were imaged and phospho-histone
H3/Flk-1-positive cells were counted over total Flk-1 population.
MI was calculated as the ratio of proliferative (phospho-histone
H3/Flk-1-positive cells) over the total number of Flk-1þ cells and
expressed as a percentage.
Flow cytometric analysis
Ten allantoides were pooled and plated in one well of 6-well
plate pre-coated with ﬁbronectin (Greiner Bio-One, Monroe, NC,
USA). The allantoides were cultured and treated as describedabove. After 5 h, cells were harvested, washed three times with
FACS buffer (PBS containing 0.1% BSA) and then incubated in the
dark at 0 1C for 30 min with FITC-conjugated rat antibodies to
antimouse-Flk-1 (15 mg/ml) in FACS buffer. Analyses of the Flk-1þ
cell population were performed using FACScan cytometer (BD
Biosciences, San Jose, CA, USA) and the data analyzed using BD
Cell Quest (BD Biosciences, San Jose, CA, USA). Resulting data
were normalized by considering the VEGF-mediated response as
100% of maximal response.
To determine mitotic index (MI) in Flk-1þ cells using ﬂow
cytometric analyses, pooled allantoic cultures were treated and
subjected to immunostaining as described above and then stained
with propidium iodide (PI)/RNAse solution (BD Biosciences, San
Jose, CA, USA). Cell cycle analyses of the Flk-1þ cells were
performed using a MoFlo Astrios High Speed Cell Sorter (Beckman
Coulter, Brea, CA, USA). MI was calculated as the ratio of Flk-1þ
cells in the G2/M phase over the total number of Flk-1þ cells and
expressed as a percentage.
Morphogenic analysis
Allantoides were cultured overnight on ﬁbronectin-precoated
Nunc 4-chambered culture slides in 1 ml complete DMEM at
37 1C, 5% CO2. The following day the media was changed and the
cells were then cultured in either SS media alone, or SS media
containing VEGF, or SM media containing VEGF and individual
eNOS inhibitors. After 5 h, the cultures were ﬁxed and permeabi-
lized as described above. The cultures were then blocked in 3%
BSA/PBS (1 h), exposed to primary and secondary antibodies to
ICAM2 (15 mg/ml, overnight, 4 1C), stained with Hoechst stain and
mounted. Cultures were imaged using a Leica TCS SP5 AOBS LSCM
and images were then collapsed into a single focal plane. To
evaluate potential inhibitory effects on vascular patterning the
ratio of the vascular area to avascular area was calculated for each
culture. This was achieved by inverting the images so that the
ICAM2-positive vascular areas were black and the ICAM2-
negative avascular area were white and then using Image J to
calculate the black to white ratio in the area delineated by the
perimeter of the allantoides. Resulting data were normalized by
considering VEGF-mediated response as 100% of maximal
response.
Statistical analysis
Experimental data are expressed as the mean7s.e.m. from at
least three independent experiments.Results
eNOS and p-eNOS(S1177) are expressed in angioblasts and embryonic
endothelial cells
Using antibodies to the angioblast/early endothelial cell mar-
ker TAL-1 (Drake et al., 1997) and to eNOS the ﬁrst expression of
eNOS in the endothelial lineage was evident at 7.2 dpc in a
subpopulation of TAL-1þ cells (data not shown). By 8.2–8.5 dpc
three distinct populations of TAL-1þ cells could be identiﬁed
based on eNOS expression and by their position in the embryo
(Drake and Fleming, 2000) (Fig. 1A and Fig. 1B). These cell types
were TAL-1þ/eNOS (Fig. 1B, white arrows) and TAL-1þ/eNOSþ
angioblasts (Fig. 1B, arrowheads) found in the lateral mesoderm,
and TAL-1þ/eNOSþ embryonic endothelial cells (EECs) of the
dorsal aortae (Fig. 1B, asterisks). We also observed a population
of eNOS expressing cells that did not express TAL-1 (Fig. 1B,
blue arrowheads). To further deﬁne eNOS expression in the
Fig. 1. eNOS is expressed in a subpopulation of angioblasts and EECs. (A and B) En face views of a whole mounted 8.5 dpc embryo (N¼4) labeled with antibodies to TAL-1
(green) and eNOS (red). (B) Higher magniﬁcation image of the boxed area depicted in (A), showing low eNOS (white arrowheads) or no eNOS (arrows) expression in TAL-
1þ angioblasts and high eNOS expression in EECs of the dorsal aorta (asterisks). Blue arrowheads designate eNOSþ/TAL-1 cells. (C) An en face view of a whole mounted
8.5 dpc embryo (N¼4) labeled with antibodies to Flk-1 (green) and eNOS (red), showing both Flk-1þ/eNOSþ (arrowheads) and Flk-1þ/eNOS (arrows) angioblasts and
Flk-1þ/eNOSþ EECs (asterisks). (D) An en face view of a whole mounted 8.5 dpc embryo (N¼4) labeled with antibodies to Flk-1 (green) and p-eNOS(S1177) (red), showing
both Flk-1þ/p-eNOS(S1177)þ angioblasts (white arrowheads) and Flk-1þ/P-eNOS angioblasts (arrows), and Flk-1þ/p-eNOS(S1177)þ expression in a subpopulation of EECs
(asterisks). Blue arrowheads designate population of p-eNOS(S1177)þ cells not expressing Flk-1. Magniﬁcation bars equal 150 mm (A) and 50 mm (B–D).
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nolabeled with antibodies to eNOS and Flk-1 (Fig. 1C). As was
the case with TAL-1 three distinct populations of Flk-1þ cells
could be identiﬁed based on eNOS expression and their position
in the embryo; they were both Flk-1þ/eNOS (Fig. 1C, arrows)and Flk-1þ/eNOSþ (Fig. 1C, arrowheads) angioblasts found in the
lateral mesoderm, and Flk-1þ/eNOSþ EECs of the dorsal aortae
(Fig. 1C, asterisks). Next, we evaluated if eNOS in Flk-1þ cells was
phosphorylated. To achieve this, 8.5 dpc embryos were immuno-
labeled with antibodies to Flk-1 and antibodies speciﬁc for eNOS
Fig. 2. p-eNOS(S1177) expression in the allantois. (A–C) Images of an 8.5d pc
allantois (N¼3) labeled with antibodies to Flk-1 (green) and to p-eNOS(S1177) (red).
(A) Confocal image depicting Flk-1þ/p-eNOS(S1177)þ cells (arrows) and Flk-1/p-
eNOS(S1177)þ cells (arrowheads). (B and C) 3D AMIRA reconstructions of the
allantois represented in (A) depicting Flk-1þ/p-eNOS(S1177)þ cells (arrows), and
Flk-1/p-eNOS(S1177)þ cells (arrowheads). (C) Side view of upper left hand area
depicted in (B). Magniﬁcation bars equal 50 mm (A).
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major downstream targets of the VEGF/Flk-1 signaling pathway in
ECs (Sessa, 2004). Analysis revealed that phosphorylated Ser1177
was observed in a subpopulation of the Flk-1þ EECs (Fig. 1D,
asterisks), and of the Flk-1þ angioblasts (Fig. 1D, white arrow-
heads). We also observed a population of isolated P-eNOS expres-
sing cells that did not express Flk-1 (Fig. 1D, blue arrowheads). In
contrast, analysis of the other phosphorylation sites on eNOS
regulated by VEGF signaling pathway showed that neither phos-
phorylated Ser617 nor Thr495 were detected in Flk-1þ cells at 8.5
dpc (Supplementary Fig. S1A–H). Taken together these ﬁndings
establish that both eNOS and eNOS phosphorylated on S1177,
hereafter referred to as p-eNOS(S1177), are expressed in angio-
blasts and EECs.
p-eNOS(S1177) expression in the allantoic vasculature recapitulates
the pattern observed in the endothelial lineage of the embryo proper
In previous studies we established the utility of cultured murine
allantois as a model system for studying vasculogenesis and
angiogenesis (Argraves et al., 2004; Argraves et al., 2002; Crosby
et al., 2005). To determine its suitability as an experimental model
for the studying of eNOS/p-eNOS regulation we evaluated if the
expression proﬁle of p-eNOS(S1177) in the allantois recapitulated that
observed in the embryo proper. Immunolabeling of 8.5 dpc allantois
with antibodies to Flk-1 and to p-eNOS(S1177) (Fig. 2A) showed that,
as was the case in the embryo proper, only a subpopulation (arrows)
of Flk-1þ EECs expressed p-eNOS(S1177). 3D AMIRA reconstructions
of the allantois depicted in Fig. 2A–C andMovie 1), serve to highlight
the Flk-1þ/p-eNOS(S1177)þ EECs (arrows) and to distinguish them
from the Flk-1/p-eNOS(S1177)þ cells (arrowheads), which were
often positioned closely apposed to forming blood vessels.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.ydbio.2012.10.020.
A role for eNOS in regulating cell proliferation in the EC lineage
Given that VEGF is both an upstream regulator of eNOS/NO
and a mediator of EC proliferation we investigated whether there
was a correlation between angioblast and/or EEC proliferation
and eNOS expression. To evaluate this, 8.5 dpc embryos were
immunolabeled with antibodies to Flk-1 and phospho-histone H3,
a marker of cell proliferation. As seen in Fig. 3A both Flk-1 (green)
and phospho-histone H3 (red) expression was detected in a
subpopulation of Flk-1þ angioblasts (arrowheads) and aortic EECs
(asterisks). Similarly to what observed in the embryo proper,
analysis of eNOS and phospho-histone H3 expression in the
8.5 dpc allantois (Fig. 3B) revealed that a subpopulation of eNOSþ
EECs were phospho-histone H3þ(arrows). In addition to prolifer-
ating EECs we also observed a population of isolated eNOSþ/
phospho-histone H3þ cells (arrowheads) that were adjacent to
eNOSþ allantoic endothelium. Taken together these ﬁndings
suggest that there is a correlation between eNOS expression and
proliferation in cells of the EC lineage.
VEGF regulates P-eNOS(S1177) expression in Flk-1þ cells
To assess the role of VEGF/Flk-1 signaling in the regulation of
p-eNOS(S1177) in cells of the EC lineage, allantoides were cultured
with and without VEGF followed by immunolabeling with anti-
bodies against p-eNOS(S1177) and the EC marker ICAM2 (Bautch
et al., 2000). As depicted in Fig. 4, p-eNOS expression in untreated
cultures was observed in a subpopulation of EECs of forming
vessels (Fig. 4A, arrows). Analysis of the VEGF treated cultures
showed an apparent increase in the number of p-eNOS(S1177)þ
EECs (Fig. 4B, arrows). Also evident in these cultures was apopulation of p-eNOS(S1177)þ cells which were closely apposed
to developing blood vessels that did not express ICAM2. That
p-eNOS(S1177)þ expression in EECs is dependent on VEGF/
Flk-1 signaling is supported by our ﬁnding that p-eNOS(S1177)
expression (red) was conﬁned to Flk-1þ cells (green) in
Fig. 3. Cell proliferation and eNOS expression in the embryo proper and in the allantois. (A) Image of an 8.5 dpc embryo labeled with antibodies to Flk-1 (green) and
phospho-histone H3 (red), showing co-expression of Flk-1 and phospho-histone H3 in a subpopulation of EECs (asterisks) and angioblasts (arrowheads). (B) Image of an
8.5 dpc allantois labeled with antibodies to eNOS (green) and phospho-histone H3 (red), showing co-expression of eNOS and phospho-histone H3 in EECs (arrows) and in a
subpopulation of cells adjacent to the forming vessels (arrowheads). Magniﬁcation bars equal 50 mm.
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worthy that, as was the case in vivo, we also observed
p-eNOS(S1177) expression in isolated Flk-1 cells (Supplementary
Fig. S2, arrowheads).
p-eNOS(S1177) expression is correlated with NO production
Having observed a correlation between cell proliferation and
eNOS expression we next sought to establish if a similar correla-
tion existed between p-eNOS(S1177) expression and NO produc-
tion. To achieve this allantoic cultures were exposed to DAF-FM
diacetate, treated with VEGF and then immunostained with
antibodies to Flk-1 and p-eNOS(S1177). The immunolabeling
depicted in Fig. 5 shows an apparent increase in the number of
Flk-1þ cells producing NO following VEGF treatment (50 ng/ml,
30 min, Fig. 5D) versus control cultures (Fig. 5C). In order to
quantify the increase in NO producing Flk-1þ cells, allantoides
were pooled (N¼10 per sample) and trypsinized. Following 18 h
in culture, cells were cultured in presence of DAF-FM diacetate
and then treated with VEGF (50 ng/ml, 30 min). As seen in
Supplementary Fig. S3A and B, VEGF induced an increase in NO
producing Flk-1þ cells. Supplementary Fig. S3C shows that the
observed VEGF-induced NO production was statistically signiﬁ-
cant (50%) and it was correlated with an increase in
p-eNOS(S1177) expression levels (55%). To exclude a role for
iNOS-mediated NO production, allantoic cultures were immunos-
tained with antibodies to Flk-1 and iNOS. Analysis revealed that
VEGF responsive Flk-1þ cells do not express iNOS in these culture
conditions (Supplementary Fig. S4A–C). However, iNOS expres-
sion was detected in a population of Flk-1 cells (Supplementary
Fig. S4A–C, arrows). The lack of iNOS expression in Flk-1þ cells of
the allantoic culture is consistent with our in vivo analysis of iNOS
expression, which also showed that Flk-1þ cells did not expressiNOS, whereas iNOS expression was detected in a subpopulation
of Flk-1 cells (Supplementary Fig. S5A–F).
Antagonists of NO production decrease VEGF-mediated cell division
in angioblast and embryonic endothelial cells
Our ﬁndings that VEGF acts to increase the levels of
p-eNOS(S1177) and NO in Flk-1þ cells and that p-eNOS(S1177)
expression is associated with EC division, led us to assess the
effects of eNOS/NO inhibitors on VEGF-mediated angioblast
and/or EEC division. Fig. 6A shows representative FACS analyses
of the Flk-1þ cell population in serum starved allantoic cultures,
VEGF-treated cultures, and cultures treated with VEGF plus L-NIO,
an eNOS inhibitor, or resveratrol, an NO scavenger. Our analysis
showed that VEGF increased the number of Flk-1þ cells as
compared to serum starved control cultures and that this increase
was attenuated by the eNOS/NO inhibition. Quantitation in Fig. 6B
showed that VEGF treatment increased the number of Flk-1þ cells
by 30%, while inhibition of eNOS/NO under all conditions resulted
in reductions in Flk-1þ cells. While co-treatment with resveratrol
did not result in a statistically signiﬁcant reduction, L-NIO
decreased the VEGF-mediated increase in Flk-1þ population by
32%, respectively. FACS analyses revealed that the inhibitory
effects of L-NIO and resveratrol were not due to an increase in
apoptosis as determined by propidium iodide staining (data not
shown).
To investigate if the effects of eNOS/NO antagonist on Flk-1þ
cell numbers were due to reduced cell proliferation, Flk-1þ cells
were isolated from VEGF-treated allantoic cultures co-treated
with L-NIO. Isolated Flk-1þ cells were labeled with propidium
iodide and analyzed for changes in cell cycle by ﬂow cytometry.
The mitotic indexes (MIs) were determined by calculating the
ratio of Flk-1þ in the G2/M phase and are expressed as a
Fig. 4. VEGF regulates p-eNOS(S1177) expression in angioblasts and EECs. (A–B)
Images of serum starved (SS, A) 8.5 dpc allantoides culture and VEGF-treated
(50 ng/ml, B) 8.5 dpc allantoides culture labeled with antibodies to ICAM2 (green),
p-eNOS(S1177) (red) and stained with Hoechst (blue). Evident in both (A) and
(B) are isolated ICAM2þ EECs that co-express p-eNOS(S1177) (arrows). (C) VEGF-
treated 8.5 dpc allantoic culture labeled with antibodies to Flk-1 (green) and
p-eNOS(S1177) (red) and stained with Hoechst (blue). Flk-1þ EECs that co-express
p-eNOS(S1177) are indicated by arrows. Magniﬁcation bars equal 50 mm.
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Materials and methodssection). As shown in Fig. 6C, VEGF
increased the number of mitotic cells by 14%. VEGF-mediatedeffects were reduced by L-NIO (4%). Taken together our ﬁndings
suggest that VEGF effects on cell proliferation are, in part,
mediated by NO.
VEGF-mediated cell division in the endothelial lineage is dependent
on phosphorylation of eNOS on Ser1177 by Akt1
Given that Akt1 acts to regulate the phosphorylation of eNOS on
Ser1177 in adult ECs (Schleicher et al., 2009) and is a downstream
target of VEGF and our ﬁndings that VEGF acts to increase the
levels of p-eNOS(S1177) and NO in Flk-1þ cells and that NO
production is associated with EC division, led us to assess whether
the VEGF induced responses we had observed in angioblasts and
EECs were mediated by Akt1. To evaluate this we utilized Akt1 null
mice (Mao et al., 2007). We ﬁrst evaluated the expression pattern
of p-eNOS(S1177) in 8.5 dpc Akt1 null embryos (Supplementary Fig.
S6A–C). In contrast to wild type embryos, p-eNOS(S1177) expression
was almost completely absent in angioblasts and EECs of the Akt1
null embryos. Consistent with a reduction in p-eNOS(S1177), analy-
sis of phospho-histone H3 expression in vivo in 8.5 dpc Akt1 nulls
showed reduced cell proliferation in both angioblasts and EECs
(Supplementary Fig. S7).
To evaluate the effects of the loss of Akt1 on VEGF-mediated
p-eNOS(S1177) expression and NO production, 8.5 dpc allantoic
cultures generated from 8.5 dpc Akt1 null embryos were treated
with 50 ng/ml VEGF and immunolabeled with antibodies to Flk-1
and p-eNOS(S1177) (Fig. 7A and B). Comparison of the numbers of
Flk-1þ cells expressing p-eNOS(S1177) between wild type, hetero-
zygous and homozygous allantoic cultures (Fig. 7C) showed that
p-eNOS(S1177) expression was reduced by 45% and 80% in hetero-
zygous and homozygous allantoic cultures compared to controls,
respectively. Next, to evaluate the relationship between the PI3K/
Akt1-mediated p-eNOS(S1177) expression and cell proliferation,
cell proliferation in VEGF-treated allantoic cultures was inhibited
pharmacologically and genetically, by using the PI3K inhibitor
LY294002 in wild type allantoides and allantoides isolated from
Akt1 heterozygous and homozygous mouse embryos, respec-
tively. Mitotic Indexes generated by calculating the ratio of
proliferative (phospho-histone H3þ) over the total Flk-1þ cells
indicated that Akt1 expression is necessary for the increase of cell
proliferation in angioblasts and EECs (Fig.7D). Consistent with
these results our analysis of NO producing Flk-1þ cells in the
above cultures demonstrate a similar relationship between Akt1
and NO production (Supplementary Fig. S8A–C). A similar inhibi-
tory response on VEGF-mediated increase in p-eNOS(S1177)
expression and NO production was observed by using chemical
inhibitors of the VEGF, Akt1 and eNOS signaling pathways
(Supplementary Fig. S9A and B).
VEGF-mediated vascular patterning is regulated by Akt1-mediated
P-eNOS expression and NO production during development
As the number of Flk-1þ cells (angioblasts and/or EECs) is
relevant to the patterning of blood vessels (LaRue et al., 2004;
LaRue et al., 2003), we next sought to determine if the decrease in
Flk-1þ cell proliferation observed in response to PI3K/Akt1 dele-
tion altered the VEGF-mediated vascular pattern. Analysis of 8.5
dpc wild type and Akt1 null allantoic cultures treated with VEGF
and immunolabeded with antibodies to Flk-1 showed that the
absence of Akt1 dramatically changed the number and patterning
of allantoic vessels (Supplementary Fig. S10).
To investigate the role of NO in VEGF/Akt-1-mediated vascular
patterning we used pharmacological inhibitors of Akt1 and
NO (Fig. 8A). Comparison of control, serum starved cultures to
VEGF-treated cultures showed that VEGF dramatically increased
the vascularized area (black areas) of the culture with a
Fig. 5. VEGF regulates intracellular NO production in angioblasts and EECs. (A–F) Images of control (A, C and E) and VEGF-treated (50 ng/ml, 30 min, B, D and F) 8.5 dpc
allantoic cultures cultured in the presence DAF-FM diacetate for the detection of intracellular NO production (green), labeled with antibodies to Flk-1 (red) and stained
with Hoechst (blue). (C) and (D) are images of NO producing cells from ﬁelds showed in (A) and (B), respectively. (E) and (F) are images of Flk-1þ cells from ﬁelds showed
in (A) and (B), respectively. Flk-1þ cells that produce NO are indicated by arrowheads. Magniﬁcation bars equal 150 mm.
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cultures co-treated with LY294002, L-NIO or resveratrol showed
alterations in the patterning of the blood vessels as compared to
the VEGF control. Comparisons between vascularized and avascu-
lar areas revealed that exogenous VEGF increased vascularized
areas as compared to control by 70% and that LY294002, L-NIO and
resveratrol reduced the VEGF-induced ratio by 57%, 79% and 68%,
respectively (Fig. 8B). It is important to note that although the
resveratrol-mediated inhibition was 68% it was not found to be
statistically signiﬁcant based on three independent experiments.Discussion
Our study is the ﬁrst to show that eNOS and its phosphorylated
isoform on Ser1177, p-eNOS(S1177), are expressed in endothelial
progenitor cells (angioblasts) and that the Akt1-dependent phos-
phorylation on Ser1177 in angioblasts and embryonic endothelial
cells (EECs) plays a prominent role in regulating NO production.
The expression of both eNOS and p-eNOS(S1177) at the earliest
stages of vascular development (7.2–8.5 dpc) establishes that the
expression of eNOS in angioblasts and EECs is not dependent on
Fig. 6. VEGF mediated proliferation in Flk-1-positive cells is attenuated by NO antagonists. (A) Representative FACS analyses of the Flk-1þ cells from pooled allantois
cultures treated for 5 hours with: serum starvation (SS) media only, VEGF (50 ng/ml), VEGF plus L-NIO (100 mM) and VEGF plus resveratrol (20 mM). (B) Statistical analysis
of the FACS data from three independent experiments conducted following methods described in (A). (C) Mitotic indexes derived from FACS analysis of DNA content of
ﬁxed Flk-1þ cells (N¼3) from serum starved HUVECs treated with: serum starvation (SS) media only, VEGF (50 ng/ml) and VEGF plus L-NIO (100 mM). Signiﬁcance was set
at *po0.05 (N¼3).
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Fig. 7. VEGF mediated p-eNOS(S1177) expression and cell proliferation in Flk-1-positive cells is dependent on Akt1. (A and B) Confocal images of an intact Akt1 homozygous
allantoic culture (N¼4) that was treated with VEGF (50 ng/ml, 30 min), labeled with antibodies to Flk-1 (green) and p-eNOS(S1177) (red) and stained with Hoechst (blue). (C)
Statistical analysis of isolated Flk-1þ allantoic cells that were treated with VEGF (50 ng/ml, 30 min), labeled with antibodies to Flk-1 and p-eNOS(S1177) and stained with
Hoechst, showing the differences in p-eNOS(S1177)þ/Flk-1þ cell ratios following VEGF treatment (30 min) between wild type, heterozygous and homozygous. (D) Mitotic
indexes derived from immunohistochemical analysis of phospho-histone H3þ/Flk-1þ wild type cells treated with serum starved media only (SSM), VEGF, VEGF plus LY294002,
and phospho-histone H3þ/Flk-1þ heterozygous and homozygous cell following VEGF treatment. Magniﬁcation bars equal 150 mm. Signiﬁcance was set at *po0.05 (N¼3).
C. Gentile et al. / Developmental Biology 373 (2013) 163–175172the initiation of blood ﬂow which occurs at 9.0–9.5 dpc (Mu and
Adamson, 2006), nor signaling by vascular smooth muscle cells
(SMCs), which ﬁrst appears at 10.5 dpc (Esner et al., 2006;
Wasteson et al., 2008). This ﬁnding suggested that NO had
role(s) in vascular development that have not previously been
described. The fact that we observed both TAL-1þ/eNOS- and Flk-
1þ/eNOS angioblasts suggest that NO is not involved in EC
lineage determination, which is compatibile with the studies of
others showing that NO can mediate EC division (Dai and Faber,
2010; Oliveira et al., 2008; Papapetropoulos et al., 1997;
Polytarchou and Papadimitriou, 2005). We therefore hypothesized
that NO acts to mediate angioblast and EEC division and thus
vasculogenic and/or angiogenic blood vessel formation. In support
of such a role, we showed that following VEGF treatment p-
eNOS(S1177) levels are increased and that this increase is correlated
with elevated NO production in both proliferating angioblasts and/orEECs in vivo. It is important to note that our immunostaining
highlighted the presences of p-eNOS(S1177) expressing cells that were
neither Flk-1 nor TAL-1 positive. This observation suggests that in
addition to previously described cell types that express eNOS, such
as cardiac myocytes, neurons, and renal epithelial cells (Michel and
Feron, 1997), there may be additional cell types and/or progenitor
cells that fall outside the endothelial-hematopoietic lineage that also
express eNOS.
A role for NO as a downstream target of VEGF/Flk-1-mediated
angioblast and/or EEC division is highlighted in our in vitro
studies evaluating the effects of PI3K/Akt1 and eNOS/NO antago-
nists on VEGF/Flk-1 signaling pathway. These studies showed that
pharmacological inhibition of the eNOS/NO pathway decreased the
number Flk-1þ cells in VEGF treated allantoic cultures (Fig. 6) and
that the deletion of Akt1 dramatically reduced VEFG-mediated
Flk-1þ cell division (Fig. 7). Based on the pattern of Flk-1 and eNOS
Fig. 8. VEGF mediated vascular patterning is altered by PI3K/Akt1 and eNOS/NO antagonists. (A) Representative images of allantois cultures treated for 5 h with: serum
starvation (SS) media only, VEGF (50 ng/ml), VEGF plus LY294002 (20 mM), VEGF plus L-NIO (100 mM) and VEGF plus resveratrol (20 mM), and labeled with antibody to
ICAM2. (B) Statistical analysis of vascular patterns (analyzed using black versus white ratio) from six independent experiments (N¼6) conducted as in (A). Signiﬁcance was
set at *po0.05 (N¼3).
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antagonist on VEGF-mediated cell proliferation (Fig. 6C) we spec-
ulate that the reduction in Flk-1þ cell numbers observed in
response to L-NIO and resveratrol is due to decreased proliferation
due to reduced VEGF-mediated intracellular NO. Additionally,
based on the effects of both pharmacological (i.e., LY294002) and
genetic inhibition of Akt1 on VEGF-mediated cell proliferation and
vascular pattern (Fig. 7D), we conclude that the VEGF/eNOS-
mediated response is dependent on Akt1. In support of this, the
study of Papapetropoulos et al. (1997) showed that NO is a
downstream target of VEGF/Flk-1-mediated EC division.
Our studies also suggest a mechanism by which VEGF/
Flk-1 signaling acts to mediate EC division by regulating the
phosphorylation of eNOS. This is based on our ﬁndings that VEGF
acts within 30 min to increase p-eNOS(S1177) levels and the
mitotic index in the Flk-1þ cell population isolated from allantoic
cultures treated with VEGF (as determined by both FACS and IHCanalyses, Figs. 6C and D, respectively). That the mitogenic effects
we observed in response to VEGF are speciﬁc to VEGF-mediated
phosphorylation eNOS on Ser1177 is supported by our ﬁndings
that other potential phosphorylation sites on eNOS (i.e., Ser617
and Thr495) remain unphosphorylated in these cells at this
embryonic stage (Supplementary Fig. S1). Further, our ﬁndings
demonstrating that Flk-1þ cells do not express iNOS in vitro and
in vivo (Supplementary Fig. S3A–C and Fig. S4A–C, respectively) at
stages relevant to this study exclude a VEGF mediated response
through iNOS.
A role for NO as a mediator of VEGF-induced angioblast and/or
EEC proliferation is also consistent with the changes in VEGF
mediated patterning induced by eNOS/NO antagonist (Fig. 8). In
previous studies, we have demonstrated that the proper pattern-
ing of embryonic blood vessels is dependent on the correct
number of ECs (Giles et al., 2005; LaRue et al., 2004, 2003). This
number can be altered by either increased/decreased EC lineage
C. Gentile et al. / Developmental Biology 373 (2013) 163–175174commitment or by EC proliferation. The presence of thinner and
more isolated vessel segments, as reﬂected in the black versus
white ratio analysis, induced by the eNOS/NO and Akt1 antago-
nists is indicative of a reduction in EC numbers and is in
accordance with our ﬁndings (Fig. 6). That this reduction in cell
numbers is due to inhibition of proliferation in angioblasts and/or
EECs is consistent with the study of Yue and Tomanek (2001),
which showed the ability of VEGF to induce neovascularization in
a model of cultured embryonic quail hearts by increasing the
numbers of ECs in a VEGF dose-dependent manner and by our
studies demonstrating diminished proliferation in these cells
following inhibition of Akt1 (Fig. 7D). Based on these ﬁndings,
we conclude that the changes in the patterning of allantoic
vessels observed following treatment with VEGF is due in part
to VEGF/Akt1-mediated NO production that acts to increase
angioblasts and/or EEC proliferation. Conversely, we speculate
that the alterations to the VEGF-mediated patterning of allantoic
vessels observed in cultures treated with NO and PI3K/Akt1
inhibitors are due to decreased NO production and decreased
proliferation in angioblasts and/or EECs.
This study extends the role played by NO in VEGF-mediated
proliferation to the earliest stages of vascular development and
suggests that phosphorylation of eNOS on Ser1177 is a key
regulator of VEGF-mediated vasculogenesis. In support of this
are our ﬁndings showing a strong correlation between VEGF-
mediated p-eNOS(S1177) expression and eNOS activity (i.e., NO
production) and function (i.e., VEGF-mediated Flk-1þ cell prolif-
eration and vascular patterning).Acknowledgments
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